Antitumor activity of celastrol nanoparticles in a xenograft retinoblastoma tumor model

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 2389-2398

  Li, Zhanrong ^a   Wu, Xianghua ^a   Li, Jingguo ^b   Yao, Lin ^a   Sun, Limei ^a   Shi, Yingying ^a   Zhang, Wenxin ^a   Lin, Jianxian ^a   Liang, Dan ^a   Li, Yongping ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Apoptosis; Celastrol nanoparticles; Nanopolymeric micelles; Poly(ethylene glycol) block poly(e caprolactone); SO Rb 50 cells

Indexed keywords

CELASTROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NANOPARTICLE; POLY(ETHYLENE GLYCOL)BLOCK POLY(EPSILON CAPROLACTONE); POLYCAPROLACTONE; PROTEIN BAX; PROTEIN BCL 2; SYNAPTOTAGMIN I; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HISTOLOGY; HUMAN; HUMAN CELL; HYDROPHILICITY; IC 50; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RETINOBLASTOMA; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG CARRIERS; DRUGS, CHINESE HERBAL; HUMANS; HYDROGEN-ION CONCENTRATION; LACTONES; MICE; MICE, INBRED NOD; MICE, SCID; NANOPARTICLES; NEOPLASMS, EXPERIMENTAL; POLYETHYLENE GLYCOLS; RETINOBLASTOMA; TRITERPENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84870361878     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S29945     Document Type: Article

References (41)

1. Devesa SS. The incidence of retinoblastoma. Am J Ophthalmol. 1975;80(2):263-265.
2. Bishop JO, Madson EC. Retinoblastoma. Review of the current status. Surv Ophthalmol. 1975;19(6):342-366.
3. Shields CL, Shields JA. Diagnosis and management of retinoblastoma. Cancer Control. 2004;11(5):317-327.
4. Abramson DH, Schefler AC. Update on retinoblastoma. Retina. 2004;24(6):828-848.
5. Byrne J, Fears TR, Whitney C, Parry DM. Survival after retinoblastoma: long-term consequences and family history of cancer. Med Pediatr Oncol. 1995;24(3):160-165.
6. Elison JR, Cobrinik D, Claros N, Abramson DH, Lee TC. Small molecule inhibition of HDM2 leads to p53-mediated cell death in retinoblastoma cells. Arch Ophthalmol. 2006;124(9):1269-1275.
7. Zhang H, Li B, Bai SW, Wang HJ. Constitutively active Akt contributes to vincristine resistance in human retinoblastoma cells. Cancer Invest. 2010;28(2):156-165.
8. Tao X, Cush JJ, Garret M, Lipsky PE. A phase I study of ethyl acetate extract of the chinese antirheumatic herb Tripterygium wilfordii hook F in rheumatoid arthritis. J Rheumatol. 2001;28(10):2160-2167.
9. Li H, Zhang YY, Tan HW, Jia YF, Li D. Therapeutic effect of tripterine on adjuvant arthritis in rats. J Ethnopharmacol. 2008;118(3):479-484.
10. Pinna GF, Fiorucci M, Reimund JM, Taquet N, Arondel Y, Muller CD. Celastrol inhibits pro-inflammatory cytokine secretion in Crohn's disease biopsies. Biochem Biophys Res Commun. 2004;322(3):778-786.
11. Allison AC, Cacabelos R, Lombardi VR, Alvarez XA, Vigo C. Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2001;25(7):1341-1357.
12. Wang XN, Wu Q, Yang X, Zhang LS, Wu YP, Lu C. Effects of Celastrol on growth inhibition of U937 leukemia cells through the regulation of the Notch1/NF-kappaB signaling pathway in vitro. Chin J Cancer. 2010;29(4):385-390.
13. Zhou LL, Lin ZX, Fung KP, et al. Celastrol-induced apoptosis in human HaCaT keratinocytes involves the inhibition of NF-kappaB activity. Eur J Pharmacol. 2011.
14. Yang H, Chen D, Cui QC, Yuan X, Dou QP. Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine, " is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res. 2006;66(9):4758-4765.
15. Nunes CT, Miners KL, Dolton G, et al. A novel tumor antigen derived from enhanced degradation of bax protein in human cancers. Cancer Res. 2011;71(16):5435-5444.
16. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest. 2001;107(3):241-246.
17. Nagase M, Oto J, Sugiyama S, Yube K, Takaishi Y, Sakato N. Apoptosis induction in HL-60 cells and inhibition of topoisomerase II by triterpene celastrol. Biosci Biotechnol Biochem. 2003;67(9):1883-1887.
18. Abbas S, Bhoumik A, Dahl R, et al. Preclinical studies of celastrol and acetyl isogambogic acid in melanoma. Clin Cancer Res. 2007;13(22 Pt 1): 6769-6778.
19. Li Z, Yao L, Li J, et al. Celastrol nanoparticles inhibit corneal neovascularization induced by suturing in rats. Int J Nanomedicine. 2012;7:1163-1173.
20. Cao N, Cheng D, Zou S, Ai H, Gao J, Shuai X. The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells. Biomaterials. 2011;32(8): 2222-2232.
21. Tamura S, Hosoi H, Kuwahara Y, et al. Induction of apoptosis by an inhibitor of EGFR in neuroblastoma cells. Biochem Biophys Res Commun. 2007;358(1):226-232.
22. The Association for Research in Vision and Ophthalmology. Rockville: 2010 ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Available from: http://www.arvo.org/eweb/dynamicpage.asp x?sitexarvo2&webcodeaAnimalsResearch. Accessed March 13, 2012
23. Song X, Zhou Y, Jia R, et al. Inhibition of retinoblastoma in vitro and in vivo with conditionally replicating oncolytic adenovirus H101. Invest Ophthalmol Vis Sci. 2010;51(5):2626-2635.
24. Pang X, Yi Z, Zhang J, et al. Celastrol suppresses angiogenesismediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res. 2010;70(5):1951-1959.
25. Mikhail AS, Allen C. Poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelles containing chemically conjugated and physically entrapped docetaxel: synthesis, characterization, and the influence of the drug on micelle morphology. Biomacromolecules. 2010;11(5):1273-1280.
26. Yanez JA, Forrest ML, Ohgami Y, Kwon GS, Davies NM. Pharmacometrics and delivery of novel nanoformulated PEG-bpoly(epsilon-caprolactone) micelles of rapamycin. Cancer Chemother Pharmacol. 2008;61(1):133-144.
27. Shuai X, Ai H, Nasongkla N, Kim S, Gao J. Micellar carriers based on block copolymers of poly(epsilon-caprolactone) and poly(ethylene glycol) for doxorubicin delivery. J Control Release. 2004; 98(3):415-426.
28. Talelli M, Rijcken CJ, van NCF, Storm G, Hennink WE. Micelles based on HPMA copolymers. Adv Drug Deliv Rev. 2010;62(2): 231-239.
29. Forrest ML, Yanez JA, Remsberg CM, Ohgami Y, Kwon GS, Davies NM. Paclitaxel prodrugs with sustained release and high solubility in poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelle nanocarriers: pharmacokinetic disposition, tolerability, and cytotoxicity. Pharm Res. 2008;25(1):194-206.
30. Safavy A, Raisch KP, Mantena S, et al. Design and development of water-soluble curcumin conjugates as potential anticancer agents. J Med Chem. 2007;50(24):6284-6288.
31. Kakizawa Y, Kataoka K. Block copolymer micelles for delivery of gene and related compounds. Adv Drug Deliv Rev. 2002;54(2):203-222.
32. Kannaiyan R, Shanmugam MK, Sethi G. Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer. Cancer Lett. 2011;303(1): 9-20.
33. Jarpe MB, Widmann C, Knall C, et al. Anti-apoptotic versus proapoptotic signal transduction: checkpoints and stop signs along the road to death. Oncogene. 1998;17(11 Reviews):1475-1482.
34. Choi BH, Kim W, Wang QC, et al. Kinetin riboside preferentially induces apoptosis by modulating Bcl-2 family proteins and caspase-3 in cancer cells. Cancer Lett. 2008;261(1):37-45.
35. Nehra R, Riggins RB, Shajahan AN, Zwart A, Crawford AC, Clarke R. BCL2 and CASP8 regulation by NF-kappaB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and-resistant breast cancer cells. FASEB J. 2010;24(6):2040-2055.
36. Brenner D, Mak TW. Mitochondrial cell death effectors. Curr Opin Cell Biol. 2009;21(6):871-877.
37. Robertson JD, Orrenius S. Molecular mechanisms of apoptosis induced by cytotoxic chemicals. Crit Rev Toxicol. 2000;30(5):609-627.
38. Zagurovskaya M, Shareef MM, Das A, et al. EGR-1 forms a complex with YAP-1 and upregulates Bax expression in irradiated prostate carcinoma cells. Oncogene. 2009;28(8):1121-1131.
39. Bernard D, Quatannens B, Vandenbunder B, Abbadie C. Rel/NFkappaB transcription factors protect against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by up-regulating the TRAIL decoy receptor DcR1. J Biol Chem. 2001;276(29):27322-27328.
40. Poulaki V, Mitsiades CS, Joussen AM, Lappas A, Kirchhof B, Mitsiades N. Constitutive nuclear factor-kappaB activity is crucial for human retinoblastoma cell viability. Am J Pathol. 2002;161(6):2229-2240.
41. Qu Y, Zhou F, Dai X, et al. Clinicopathologic signif icances of nuclear expression of nuclear factor-kappaB transcription factors in retinoblastoma. J Clin Pathol. 2011;64(8):695-700.